Clinical Study Details

Title	Aromatase Inhibitor Growth Study
Description	This randomized trial compares the growth promoting effects of letrozole (2.5 mg daily) to anastrozole (1 mg daily) in adolescent males, on the premixe that reduced estrogen levels allows for a longer duration of growth..
Eligibility	To be eligible for this study you must: Be male At least 10 years of age Have a Bone age of 14 years or younger Be in puberty - LH greater than 0.3 AND Testosterone greater that 15 Height less than the 5th percentile OR PAH more than 10cm BELOW the MEASURED (adjusted) midparental height (Best if BOTH criteria are met) If your child has any of the following, he CANNOT take part in the study: Is a female Primary testicular failure GH therapy is NOT an exclusion (assure GH consent is ALSO signed
Procedures	Blood tests at baseline and every six months (T, DHT, Andro, E1, E2, LH, FSH, IGF-1 IGFBP-3) Annual Bone Age DXA every 2 years
Contact	If you are interested in participating in this study and you meet the inclusion criteria, please contact: Kirk Neely, MD - 650 723- 5791
Please review the consent form for more information Consent Form Assent Form - ages 10-17